Integra LifeSciences Holdings Corporation has announced three new executive appointments. Robert T. Davis, Jr., corporate vice president and president, Specialty Surgical Solutions (SSS), has been named corporate vice president and president, Orthopedics and Tissue Technologies. Dan Reuvers, corporate vice president and president, International, will assume the role of corporate vice president and president, SSS. Glenn Coleman remains as corporate vice president, chief financial officer and principal accounting officer; now, he is also assuming oversight of the international business.
Integra: Three New Executive Appointments
2 min read Premium comments
All three executives will continue to report to Peter Arduini, Integra president and chief executive officer.
“These key leadership appointments reflect the depth and strength of our management team, enabling us to promote executives from within the company,” said Peter Arduini. “Bob, Dan and Glenn are proven leaders who have demonstrated exemplary management capabilities over the years and a track record of accomplishments that have contributed to our strong business performance.”
Glenn Coleman told OTW, “We have recently rolled out a new strategy for our international business which will generate more focus on key countries and also prioritizing our leading franchises, including orthopedics in Western Europe. We are excited about launching our Cadence ankle in Europe during the first half of the year and with a separate vertical solely focused on our European business, believe we can drive meaningful growth over the next several years.”
Dan Reuvers commented to OTW, “The Specialty Surgical Solutions division has a strong portfolio and solid strategy in place. As we’re coming off a year of solid organic growth, I’m looking forward to ensuring our products and plans support our future global growth goals. In the short term, I will be meeting with our colleagues and customers who are the best source for establishing our direction for the future.”
Bob Davis said to OTW, “My first responsibility as a leader in the Orthopedics and Tissue Technologies division is to listen and learn and find opportunities to leverage the people and talent across our organization. Our employees drive our success. We have a very strong extremity orthopedics, surgical & wound reconstruction & care portfolio with many new products and line extensions on the horizon. Together, with my leadership team we have established a clear set of priorities to create focus and alignment. This will enable us to be more agile so we can continue to deliver innovative and life changing solutions to our customers and patients.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.